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ABSTRACT: A revised structure for the Lycopodium alkaloid huperzine N is 
proposed and confirmed by synthesis. The key synthetic steps involve an 
epimerization of a cis-5-oxodecahydroquinoline to the corresponding trans 
isomer and a coupling followed by  a diastereoselective hydrogenation using 
Wilkinson’s catalyst to incorporate the pyridylmethyl moiety. This route allowed 
the alkaloid serralongamine A to be synthesized for the first time, and two 
additional steps led to the revised structure of huperzine N, both products 






























The phlegmarine alkaloids are structurally characterized by a 5,7-disubstituted 
decahydroquinoline ring and a C16N2 skeleton.1 They can be classified in four 
types, designated here as A to D, according to the relationship of the ring fusion 
hydrogens (H-4a and H-8a) with the H-7 in the decahydroquinoline ring (DHQ), 
(Figure 1).2,3 Moreover, the phlegmarine substitution pattern involves a (2-
piperidyl)methyl side chain at C-5, which can be partially (as in nitrone) or fully 
oxidized (as in pyridine), thus increasing the stereochemical variation.  
 




 After recently describing the total synthesis of I, the proposed structure of 
huperzine N,4 we revealed its misassignment. We here suggest an alternative 
structure for this natural product5,6 (i.e. 1), and confirm it by a total synthesis. 
Moreover, the synthesis of serralongamine A (2),7 featuring a pyridine instead of 
the usual piperidine ring system, is also reported. 
The putative (I) and natural huperzine (1) are clearly differentiated by their 13C 
NMR data: (i) the chemical shifts of C(2) and C(4) are more deshielded (8 and 
11 ppm, respectively) in 1 (Figure 2). These data suggest that huperzine N has 
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reported; (ii) the chemical shift of the methyl group at C(7), which resonates at δ 
19.0 in huperzine N, but at δ 22.2 in I, indicates an axial disposition, which is 
only possible in a trans-decahydroquinoline with a stereoparent of type D (see 
Figures 1 and 2). Consequently, the NMR data reported for huperzine N can be 
explained by structure 1. Building on this point of view, we synthesized 1 to 
confirm the new structural assignment. 
 
Figure 2. Differential NMR Trends Between Putative and Natural Huperzine N 
 
 
 Previous trans-phlegmarine syntheses have targeted alkaloids with the 
type C stereoparent. The synthesis of phlegmarine itself was completed by 
Comins,8 who also reported the synthesis of three related alkaloids bearing 
different substituents at the two nitrogen atoms, while Takayama9 achieved 
lycoposerramine X. The key challenges in the synthesis of these alkaloids are 
the generation of the trans-decahydroquinoline core and the stereocontrol in the 
genesis of the stereocenter at C-5 where the pyridylmethyl backbone is 
attached (Scheme 1). The two different approaches to construct the trans-
decahydroquinoline ring with the required stereochemistry in the four 
stereogenic centers are summarized in Scheme 1. Comins, applying his 
methodolgy based on pyridinium salts, prepared a polysubstituted piperidine 
that furnished the bicyclic ring by an aldol reaction. Stereoselective conjugated 
addition followed by a hydrogenation process allowed a stereochemical control 
at C-5 and in the ring fusion, respectively. In contrast, the Takayama approach 
involved the elaboration of a polyfunctionalized cyclohexane compound in which 
the four stereogenic centers were established before the cyclization leading to 







































 Our approach differs from the aforementioned both in its synthetic 
strategy and the targeted compounds, which have a decahydroquinoline core 
with a type D stereoparent.10 The synthetic plan involved the same building-
block used in our previous synthesis of cis-phlegmarines and the epimerization 
of the stereogenic center at C-4a to achieve a ketone with a trans-
decahydroquinoline ring, which would allow access to phlegmarine alkaloids 
with a new stereochemical pattern. Control of the stereochemistry at C5 through 
a substrate-directable hydrogenation process would be crucial in this synthetic 
proposal (Scheme 2). 
   
 
















































Present work: series trans type D
ring formation: phase I
stereocontrol at C-5: phase II












 Commencing the synthesis from the easily available ketone 4,11 our 
original protocol2 allowed the ring fusion to be changed from cis to trans, via the 
conversion of acetal 5 to the corresponding secondary amine and acid-induced 
epimerization at C(4a). Tosylation of the resulting 2:1 mixture of ketones 6 and 
its C4a-epimer furnished the required decahydroquinoline 7 with a trans ring 
fusion12 as a single isomer after chromatographic separation. This ketone 
reacted with a solution of the lithium anion of phosphonate 813 to give 
vinylpyridine derivative 9 in 53% yield, diastereoselectively providing the E 
isomer.14 Hydrogenation of vinylpyridine 9 using Wilkinson’s catalyst allowed 
the hydrogen to be delivered exclusively from the bottom face. Thus, a pyridine-
directed hydrogenation provided access to the valuable intermediate 10 with a 
contra-steric selectivity (Figure 3).  
   The stereoselectively-formed decahydroquinoline 10 showed the same 
relative configuration in its four stereogenic centers as the target 1 and 
serralongamine A (2). The configuration at C-5 was ascertained considering the 
multiplicity of the signal corresponding to H-4a, which implies a trans 
relationship between H-4a and H-5, both in an axial disposition. Moreover, the 


























































4 X = O













































2:1 ratio of epimers 
at the C(4a)






precursors 7 (δ 60.3) and 9 (δ 60.6), indicating that the pyridylmethyl side chain 
is not axially located  (Figure 3).15 
 
Figure 3. Transition State Leading to 10 and its Representative NMR Data  
 
 
 Removal of the tosyl group in 10 using LiAlH4 followed by reductive N-
methylation of 11 gave serralongamine A (2) in 76% yield for the two steps, 
which constitutes the first synthetic entry to a phlegmarine alkaloid embodying 
its decahydroquinoline stereoparent. The trans-decahydroquinoline 
serralongamine A differs from phlegmarine itself in the stereochemical 
relationship between the configuration at C7 and the trans ring fusion carbons, 
C4a and C8a (Figure 1). 
 It is noteworthy that the NMR data of our synthetic 2 were clearly different 
from those reported for the isolated serralongamine A in CD3OD. Since basic 
nitrogen atoms readily protonate, we were able to reproducibly obtain 1H and 
13C NMR spectra of the free base forms of serralongamine A in CD3OD 
containing NaOCD3.16 We surmised that the natural isolate corresponded to its 
ditrifluoroacetate salt. Thus, the NMR spectra of synthetic serralongamine A 
was examined by titrating a sample of the free base with TFA. For a comparison 
of NMR data for natural and synthetic serralongamine A (2) as the double TFA 
salt, see Supporting Information. As reproduced in Figure S1, NMR spectra 
identical to those reported for the natural product were obtained.  
     Having achieved 2, we were two steps from completing the new structure 
proposed for huperzine N (1). Toward this end, reduction of the pyridine ring in 





























urea·H2O2(UHP)3 led to 1 by formation of both the amine N-oxide and nitrone 
functionalities, which were further confirmed by 15N chemical shift NMR data. 
The spectroscopic data of the synthetic sample were identical in all respects to 
those reported for the natural product,5 although a side product purified together 
with huperzine N was also formed. Two-dimensional NMR spectroscopy of the 
mixture identified the minor product as the N-oxide epimer of huperzine N. 
Although the oxidation of cyclic tertiary amines normally takes place axially,17 
the presence of an equatorial substituent increases the equatorial oxidation,18 
as occurred in our substrate (C8-C8a bond). Thus, the reaction did not work 
diastereoselectively and epimeric N-oxide 12 was also formed. The 
stereostructure and the complete 1H, 13C, and 15N chemical shifts assignment of 
both epimers 1 and 12 (Figure 4) and also their protonated forms19 (see the 
Supporting Information for details) were performed from the analysis of COSY, 
ROESY,20 HSQC, HMBC, and TOCSY correlation spectra of the mixture. 
 The configuration of the new stereogenic center at the nitrogen atom in 
huperzine N was corroborated as R, on the basis of 1H and 13C chemical shift 
NMR analysis of 1 and its N-epimer 12, Thus, a clear upfield shift for C(3), 
C(4a) and C(8) was observed, due to the 1,3-cis relationship between the N→O 
bond and the axial C-H bond of these carbon atoms (Figure 4), compared with 
either the free amine base nucleus (e.g. in 2) or the N-epimeric N-oxide with the 
oxygen atom in an equatorial disposition (i.e. 12).21 The NMR data of synthetic 
huperzine N matched those described for the natural product, thus establishing 
its configuration as 1R,4aS,5S,7R,8aS. Although we have reported the racemic 
form, the phlegmarine alkaloids have always shown an R absolute configuration 
in the carbon bonded to the methyl group in the decahydroquinoline ring. Thus, 
the relative configuration allowed the absolute configuration to be proposed. 
 
Figure 4. Characteristic NMR data and Selected NOEs of huperzine N (1), 







 In summary, in this work on the phlegmarine subset of Lycopodium 
alkaloids, the first total synthesis of serralongamine A and the revised structure 
of huperzine N have been accomplished. The absolute configuration of the 
huperzine N was established and the NMR data of the serralongamine A in its 
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General. All reactions were carried out under an argon atmosphere with dry, 
freshly distilled solvents under anhydrous conditions. All product mixtures were 
analyzed by thin-layer chromatography using TLC silica gel plates with a 
fluorescent indicator (λ = 254 nm). Analytical thin-layer chromatography was 
performed on SiO2 (Merck silica gel 60 F254), and the spots were located by UV 
light or/and a 1% KMnO4 aqueous solution or hexachloroplatinate reagent. 
Chromatography refers to flash chromatography and was carried out on SiO2 
(silica gel 60 ACC, 230-240 mesh). Drying of organic extracts during the 
reaction workup was performed over anhydrous Na2SO4. Chemical shifts of 1H 
and 13C NMR spectra are reported in ppm downfield (δ) from Me4Si. All NMR 
data assignments are supported by gCOSY and gHSQC experiments.  
 (4aRS,7RS,8aRS)-7-Methyl-1-(4-methylphenylsulfonyl)-5-oxodeca-
hydroquinoline ethylene acetal (5). From crystallized keto ester 3 (536 mg, 
1.27 mmol), following the procedure previously described,11 ketone 4 was 
obtained and used in the next step without purification. After acetalization2 of 4 
and the purification step by chromatography (5% to 25% EtOAc in hexanes), 5 
(373 g, 80%) was obtained as a white solid: Rf = 0.71 (1:1 EtOAc/hexanes); mp 
100 ºC. For NMR data, see ref. 2. 
 (4aRS,7SR,8aSR)-7-Methyl-5-oxodecahydroquinoline (6). Operating as 
previously described,2 starting from 5 (373 mg, 1.02 mmol), 6, a 2:1 mixture of 
epimers at C(4a), was obtained (110 mg) as a colorless oil, which was used 
directly in the next step. For NMR data, see ref. 2.  
(4aRS,7SR,8aSR)-7-Methyl-5-oxo-1-(4-methylphenylsulfonyl)decahydro-





its epimer (110 mg) in CH2Cl2 (8 mL) was added a solution of TsCl (214 mg, 
1.12 mmol, 1.1 equiv) in CH2Cl2 (4 mL) followed by Et3N (0.17 mL, 1.23 mmol, 
1.2 equiv). The mixture was stirred at rt for 6 h and diluted with CH2Cl2 (20 mL). 
The organics were washed with brine (2 x 5 mL), dried, concentrated, and 
purified by chromatography (5% to 25% EtOAc in hexanes) to yield 
successively 4 (59 mg) and 7 (121 mg, 38% in three steps, 57% brsm) as a 
white solid: Rf = 0.35 (25% EtOAc/ hexanes); mp 108 ºC; 1H NMR (CDCl3, 400 
MHz) δ 0.81 (d, J = 7.2 Hz, 3H, CH3), 1.32 (m, 1H, H-4ax), 1.64 (m, 1H, H-3ax), 
1.76 (m, 1H, H-3eq), 2.00 (dd, J = 12.8, 3.6 Hz, 1H, H-4eq), 2.15 (dt, J = 13.6, 
2.4 Hz, 1H, H-6ax), 2.23 (dm, J = 12.4 Hz, 1H, H-8eq), 2.33 (td, J = 13.6, 4.6 
Hz, 1H, H-8ax), 2.40 (masked, H-7), 2.42 (s, 3H, CH3Ar), 2.46 (qd, 1H, J = 11.4, 
3.2 Hz, H-4a), 2.56 (dd, J = 11.6, 4.0 Hz, 1H, H-6eq), 2.66 (td, J = 11.2, 3.2, 1.6 
Hz, 1H, H-2ax), 2.89 (td, J = 11.4, 4.0 Hz, 1H, H-8a), 4.13 (dtd, J = 12.8, 4.0, 
1.2 Hz, 1H, H-2eq), 7.30 (d, J = 8.4 Hz, 2H, o-Ts), 7.68 (d, J = 8.4 Hz, 2H, m-
Ts); 13C NMR (100 MHz, CDCl3) δ 18.9 (CH3), 21.6 (ArCH3), 23.5 (C-4), 24.4 (C-
3), 28.5 (C-7), 36.1 (C-8), 47.3 (C-6), 49.3 (C-2), 53.1 (C-4a), 60.3 (C-8a), 127.3 
(m-Ts), 129.8 (o-Ts), 137.1 (ipso-Ts), 143.6 (p-Ts), 209.1 (C-5).  HRMS (ESI-
TOF) m/z: [M+H]+ calcd for C17H24NO3S 322.1471, found 322.1464. 
 (E)- (4aRS,7SR,8aRS)-7-Methyl-1-(4-methylphenylsulfonyl)-5-(pyridin-2- 
ylmethylene)decahydroquinoline (9). Both the pyridine phosphonate 8 and 
decahydroquinoline 7 were previously dried by azeotroping with benzene. To a 
stirred solution of phosphonate 8 (227 mg, 1 mmol, 5 equiv) in THF (3 mL) at -
78 ºC was added n-BuLi (1.6 M in hexanes, 0.52 mL, 0.84 mmol, 4.5 equiv). 





the decahydroquinoline 7 (60 mg, 0.187 mmol) in THF (1.2 mL) was added 
dropwise via syringe at -78 ºC. The reaction mixture was stirred for 30 min at -
78 ºC, 1 h at -30 ºC, and 6 h at 0 ºC, and quenched with sat. aq. NH4Cl (1 mL) 
and water (1 mL). The mixture was extracted with EtOAc (2 × 3 mL) and the 
combined organic extracts were dried, concentrated, and purified by 
chromatography (5% to 40% EtOAc in hexanes) to give 9 (39 mg, 53%) as a 
white solid: Rf = 0.49 (50% hexane/EtOAc); mp 128 ºC; 1H NMR (400 MHz, 
CDCl3) δ 0.77 (d, J = 7.2 Hz, 3H, CH3), 1.31 (qd, 1H, J = 12.4, 2.0 Hz, H-4ax), 
1.68 (m, 1H, H-3), 1.82 (m, 1H, H-3), 1.95 (dm, J = 13.2 Hz, 1H, H-4eq), 2.03 
(dd, J = 12.6, 4.4 Hz, 1H, H-8eq), 2.12 (m, 1H, H-6ax), 2.15 (m, 1H, H-7), 2.19 
(m, 1H, H-8ax), 2.24 (brt, J =  12.0 Hz, 1H, H-4a), 2.42 (s, 3H, ArCH3), 2.91 
(ddd, J = 13.2, 8.8, 4.4 Hz, 1H, H-8a), 2.94 (td, 1H, J = 12.8, 5.2 Hz, H-2ax), 
3.07 (dt, J = 13.2, 2.0 Hz, 1H, H-6eq), 3.97 (dt, J = 12.8, 5.2 Hz, 1H, H-2eq), 
6.31 (s, 1H, C=CH), 7.07 (dd, J = 7.6, 4.8 Hz, 1H, H-5 py), 7.13 (d, J = 8.0 Hz, 
1H, H-3 py), 7.28 (d, J = 8.4  Hz, 2H, o-Ts), 7.59 (td, J = 7.6, 2.0 Hz, 1H, H-4 
py), 7.69 (d, J = 8.4 Hz, 2H, m-Ts), 8.54 (dm, J = 4.8 Hz, 1H, H-6 py); 13C NMR 
(100 MHz, CDCl3, HSQC) δ 18.2 (CH3), 21.7 (CH3Ar), 24.5 (C-3), 25.8 (C-4), 
29.3 (C-7), 35.2 (C-6), 38.1 (C-8), 46.3 (C-4a), 46.8 (C-2), 60.6 (C-8a), 121.2 
(C-5 py), 124.0 (C-3 Py), 124.1 (=CH), 127.3 (o-Ts), 129.7 (m-Ts), 136.0 (C-4 
Py), 137.3 (p-Ts), 143.3 (ipso-Ts), 144.7 (C-5), 149.3 (C-6 Py), 157.3 (C-2 Py). 
HRMS (ESI-TOF) m/z: [M+H]+ calcd for C23H29N2O2S 397.1944, found 
397.1953. 
   (4aRS,5RS,7SR,8aRS)-7-Methyl-5-(pyridin-2-ylmethyl)-1-(4-methylphenyl-





mmol) in MeOH (7 mL) was added Wilkinson’s catalyst RhCl(PPh3)3 (16 mg, 
0.017 mmol, 25 mol %) at rt. The resulting mixture was rapidly evacuated and 
backfilled with H2 three times and then stirred under an atmosphere of H2 for 72 
h. The mixture was concentrated, and purified by chromatography (5% to 25% 
EtOAc in cyclohexane) to give 10 (17 mg, 63%): Rf = 0.5 (1:1 
EtOAc/cyclohexane): 1H NMR (400 MHz, CDCl3) δ 0.80 (d, J = 7.2 Hz, 3H, 
CH3), 0.91 (qd, J = 12.4, 6.2 Hz, 1H, H-4ax), 1.20 (m, 2H, H-6), 1.34 (qd, J = 
12.4, 3.2, 1H, H-4a), 1.65 (m, 2H, H-3), 1.80 (m, 1H, H-5), 1.86 (td, J = 12.4, 4.8 
Hz, 1H, H-8ax), 1.94 (dm, J = 12.4 Hz, 1H, H-8eq), 2.00 (m, 1H, H-7), 2.12 (dm, 
J = 12.0 Hz, 1H, H-4eq), 2.30 (dd, J = 13.4, 8.8 Hz, 1H, CH2Py), 2.42 (s, 3H, 
ArCH3), 2.94-3.00 (m, 2H, H-2ax, H-8a), 3.11 (dd, J = 13.4, 4.0 Hz, 1H, CH2Py), 
3.97 (dt, J = 13.2, 5.6 Hz, 1H, H-2eq), 7.04 (d,  J = 8.0 Hz, 1H, H-3 Py), 7.08 (m, 
1H, H-5 Py), 7.28 (d, J = 8.4 Hz, 2H, o-Ts), 7.55 (td,  J = 7.6, 1.6 Hz, 1H, H-4 
Py), 7.68 (d, J = 8.0 Hz, 2H, m-Ts), 8.50 (dm, J = 4.0 Hz, 1H, H-6 Py); 13C NMR 
(100 MHz, CDCl3, HSQC) δ 18.3 (CH3), 21.6 (ArCH3), 25.1 (C-3), 27.4 (C-4), 
27.5 (C-7), 36.8 (C-6), 37.1 (C-8), 37.3 (C-5), 42.3 (CH2Py), 45.6 (C-4a), 47.3 
(C-2), 59.8 (C-8a), 121.1 (C-5 Py), 124.0 (C-3 Py), 127.2 (o-Ts), 129.7 (m-Ts), 
136.2 (C-4 Py), 138.4 (p-Ts), 143.0 (ipso-Ts), 149.4 (C-6 Py), 161.1 (C-2 Py). 
HRMS (ESI-TOF) m/z: [M+H]+ calcd for C23H31N2O2S 399.2101, found 
399.2116. 
   (4aRS,5RS,7SR,8aRS)-7-Methyl-5-(pyridin-2-ylmethyl)decahydro-
quinoline (11). A solution of sulfonamide 10 (17 mg, 0.043 mmol) in anhydrous 
THF (1 mL) was added to a stirred suspension of LiAlH4 (16 mg, 0.43 mmol) in 





addition of one drop of water, another of aqueous 15% NaOH, and three drops 
of water. The mixture was diluted with CH2Cl2, filtered through a pad of Celite®, 
and washed thoroughly with CH2Cl2. Evaporation of the solvent gave 11, which 
was pure enough to be used in the following step. An analytical sample of 
secondary amine 11 was obtained by chromatography on alumina (1% to 5% 
MeOH in CH2Cl2): Rf = 0.22 (5:95 MeOH:CH2Cl2);  1H NMR (400 MHz, CDCl3) δ 
0.91 (d, J = 7.2 Hz, 3H, CH3), 0.92 (qd, J = 12.0, 3.2 Hz, 1H, H-4a), 1.09 (qd, J 
= 12.0, 4.0 Hz, 1H, H-4ax), 1.20-1.25 (m, 2H, 2H-6), 1.44 (td, J = 12.0, 4.2 Hz, 
1H, H-8ax), 1.52 (dt, J = 12.4, 2.0 Hz, 1H, H-8eq), 1.53 (m, 1H, H-3eq), 1.71 (tt, 
J = 13.2, 3.2 Hz, 1H, H-3ax), 1.82 (m, 1H, H-5), 2.01 (m, 1H, H-7eq), 2.14 (dd, J 
= 13.0, 3.0 Hz, 1H, H-4eq), 2.30 (dd, J = 13.2, 10.0 Hz, 1H, CH2Py), 2.47 (ddd, 
1H, J = 11.2, 10.0, 4.0 Hz, H-8a),  2.66 (td, 1H, J = 12.2, 3.0 Hz, H-2ax), 3.07 
(dm, J = 12.0 Hz, 1H, H-2eq), 3.14 (dd, J = 13.2, 4.0 Hz, 1H, CH2Py), 7.06-7.09 
(m, 2H, H-3 Py, H-5 Py), 7.55 (td, J = 8.0, 1.6 Hz, 1H, H-4 Py), 8.52 (dd, J = 5.2, 
2.0 Hz, 1H, H-6 Py); 13C NMR (100 MHz, CDCl3) δ 19.2 (CH3), 27.2 (C-3), 27.5 
(C-7), 28.8 (C-4), 36.4 (C-5), 37.6 (C-6), 39.4 (C-8), 41.9 (CH2Py), 47.0 (C-2), 
48.4 (C-4a), 56.2 (H-8a), 120.9 (C-5 Py), 123.9 (C-3 Py), 136.1 (C-4 Py), 149.4 
(C-6 Py), 161.8 (C-2 Py). HRMS (ESI-TOF) m/z: [M+H]+ calcd for C16H24N2 
245.2012, found 245.2009. 
   (4aRS,5RS,7SR,8aRS)-1,7-Dimethyl-5-(pyridin-2-ylmethyl)decahydro-
quinoline (rac-serralongamine A, 2). To a solution of the above crude amine 
11 (10 mg, 0.043 mmol) in MeOH (2.3 mL) was added 37% aqueous 
formaldehyde (24 mL, 0.328 mmol) and NaBH3CN (18 mg, 0.287 mmol) at 0 ºC, 





the crude was purified on neutral alumina (CH2Cl2 to 5% MeOH in CH2Cl2) to 
give 2 (8.4 mg, 76% over two steps from 10): Rf = 0.70 (5% CH3OH in CH2Cl2). 
This sample was dissolved in CD3OD and NaOCD3 (0.1 M in CD3OD) was 
added. 1H and 13C NMR spectra of the free base were obtained:  1H NMR (400 
MHz, CD3OD, NaOCD3) δ 0.90 (d, J = 7.6 Hz, 3H, CH3), 1.10-1.15 (masked, 1H, 
H-4a), 1.11 (br q, J = 12.0 Hz, 1H, H-4ax), 1.15 (br d, J = 12 Hz, 1H, H-6eq), 
1.25 (td, J = 12.4, 4.4 Hz, 1H, H-6ax), 1.35 (td, J = 12.4, 4.8 Hz, 1H, H-8ax), 
1.65-1-75 (m, 2H, 2H-3), 1.80-1.92 (m, 2H, H-5 and H-8a), 1.93 (dm, J = 12.0 
Hz, 1H, H-8eq), 2.03 (m, 1H, H-7), 2.16 (dm, J = 11.8 Hz, 1H, H-4eq), 2.18 (td, 
J = 12.8, 3.2 Hz, 1H, H-2ax), 2.24 (s, 3H, CH3), 2.30 (dd, J = 13.2, 10.4 Hz, 1H, 
CH2py), 2.88 (dm, J = 12.0 Hz, 1H, H-2eq), 3.19 (dd, J = 13.2, 4.0 Hz, 1H, 
CH2py), 7.24 (dd, J = 7.6, 4.8 Hz, 1H, H-5 py), 7.25 (t, J = 7.4 Hz, 1H, H-3 py), 
7.73 (tt, J = 7.6, 1.6 Hz, 1H, H-4 py), 8.42 (dm, J = 4.8, 1H, H-6 py). 13C NMR 
(100 MHz, CD3OD, NaOCD3) δ 19.5 (CH3), 26.1 (C-3), 28.5 (C-7), 29.6 (C-4), 
36.6 (C-8), 37.8 (C-5), 38.0 (C-6), 42.6 (CH2py), 43.1 (NCH3), 47.8 (C-4a), 58.5 
(C-2), 64.8 (C-8a), 122.7 (C-3 py), 125.7 (C-5 py), 138.4 (C-4 py), 149.5 (C-6 
py), 162.6 (C-2 py). HRMS (ESI-TOF) m/z: [M+H]+ calcd for C17H27N2  
259.2168, found 259.2169.  
Spectra matching the reported spectra of (-)-serralongamine A6 were obtained 
after the addition of TFA in CD3OD to the above sample of 2: 1H (400 MHz, 
CD3OD, TFA) δ 0.95 (d, J = 7.6 Hz, 3H, CH3), 1.15 (br d, J = 13.2 Hz, 1H, H-
6eq), 1.41 (td, J = 12.8, 4.8 Hz, 1H, H-6ax), 1.44 (td, J = 12.4, 4.4 Hz, 1H, H-
4ax), 1.53 (qd, J = 12.0, 2.8 Hz, 1H, H-4a), 1.64 (td, J = 12.4, 4.8 Hz, 1H, H-





2.15 (br d, J = 12.4 Hz, 1H, H-8eq), 2.22 (br d, J = 12.0 Hz, 1H, H-7eq), 2.24 
(m, 1H, H-4eq), 2.72 (dd, J = 14.4, 10.4 Hz, 1H, CH2py), 2.86 (s, 3H, NCH3), 
3.12 (td, J = 13.0, 3.2 Hz, 1H, H-2ax), 3.15 (td, J = 12.2, 4.0 Hz, 1H, H-8a), 3.52 
(br, J = 13.0 Hz, 1H, H-2eq), 3.56 (dd, J = 14.4, 4.0 Hz, 1H, CH2py), 7.85 (ddd, 
J = 7.2, 5.6,0.8 Hz, 1H,  H-5py), 7.88 (d, J = 8.0 Hz, 1H, H-3py), 8.54 (td, J = 
8.0, 1.6 Hz, 1H, H-4py), 8.77 (d, J = 5.6 Hz, 1H, H-6py); 1C NMR (100 MHz, 
CD3OD, TFA) δ 18.3 (CH3), 24.0 (C-3), 27.1(C-4), 28.1 (C-7), 33.8 (C-8), 36.8 
(C-6), 37.5 (C-5), 37.9 (CH2py), 41.4 (NCH3), 46.3 (C-4a), 57.4 (C-2), 66.0 (C-
8a), 126.3(C-5py), 129.4 (C-3py), 142.8 (C-6py), 147.8 (C-4py), 157.7 (C-2py). 
 
    (1RS,4aSR,5SR,7RS,8aSR)-1,7-Dimethyl-5-(2,3,4,5-tetrahydropyridine 1-
oxide)decahydroquinoline N-oxide (Huperzine N, 1). To a stirred solution of 
2 (8 mg, 0.031 mmol) in AcOH (0.25 mL) was added PtO2 (20% w/w, 2 mg) at 
rt. The resulting mixture was evacuated and backfilled with hydrogen 3 times 
and then stirred under an atmosphere of H2 for 16 h. The mixture was diluted 
with CH2Cl2 (2 mL) before it was filtered through a pad of celite and washed 
through with CH2Cl2. The filtered solution was washed with 1 N NaOH, dried, 
and concentrated. To a solution of the above crude diamine in MeOH/ CH2Cl2 
(1:1; 0.2 mL) were added in one portion UHP (30 mg, 0.31 mmol) and 
Na2WO4·2H2O (2 mg, 0.006 mmol) and the mixture was stirred at rt for 72 h. 
After concentration, CH2Cl2 was added and the reaction mixture was filtered, 
concentrated and purified by chromatography (2.5 to 10% MeOH in CH2Cl2 and 





ratio) as a colorless oil, which solidified on standing: Rf = 0.20 (80/20/2 
CHCl3/MeOH/NH3). 
Data for huperzine N (1): 1H NMR (400 MHz, CDCl3) δ 0.93 (d, J = 7.2 Hz, 3H, 
CH3), 1.12 (qd, J = 12.0, 3.0 Hz, 1H, H-4ax), 1.28 (masked, 1H, H-6eq), 1.40 
(td, J = 12.0, 4.0 Hz, 1H, H-6ax), 1.58 (br d, J = 13.0 Hz, 1H, H-3eq), 1.68 (m, 
2H, H-4’), 1.80 (m, 2H, H-4a, H-8ax), 1.88 (m, 2H, H-5’), 1.88 (masked, 1H, 
CH2py), 2.05 (m, 1H, H-4eq), 2.10 (1H, m, H-8eq), 2.21 (m, 1H, H-5), 2.38 
(masked, 1H, H-3ax), 2.40 (t, J = 6.0 Hz, 2H, H-3’), 2.98 (dd, J = 12.0, 3.0 Hz, 
1H, CH2py), 2.90 (td, J = 11.5, 3.2 Hz, 1H, H-8a), 3.10 (s, 3H, NCH3), 3.14 (ddd, 
J = 12.0, 11.0, 3.0 Hz, 1H, H-2ax), 3.46 (br d, J = 12.0 Hz, 1H, H-2eq), 3.75 (t, J 
= 6.4 Hz, 2H, H-6’); 13C NMR (100 MHz, HSQC) δ 18.9 (C-4’), 19.0 (CH3), 20.3 
(C-3), 23.3 (C-5’), 27.0 (C-4), 27.1 (C-7), 29.9 (C-3´), 30.1 (C-8), 32.4 (C-5), 
36.7 (CH2py), 36.8 (C-6), 41.1 (C-4a), 57.6 (NCH3), 58.5 (C-6’), 69.1 (C-2), 73.8 
(C-8a), 148.0 (C-2’); 15N (50 MHz, deduced from 1H-15N HMBC correlations) δ 
114.7 (N-oxide), 271.7 (nitrone). HRMS (ESI-TOF) m/z: [M+H]+ calcd for 
C17H31N2O2 295.2380; found 295.2374. 
Data for N-epi-huperzine N (12): 1H NMR (400 MHz, CDCl3) δ 0.99 (d, J = 7.2 
Hz, 3H, CH3), 1.20 (masked, 1H, H-4ax), 1.30 (m, 1H, H-4a), 1.35 (m, 1H, H-6), 
1.40 (m, 1H, H-6), 1.45 (td, J = 12.0, 3.0 Hz, 1H, H-8ax), 1.68 (m, 1H, H-3eq), 
1.68 (m, 2H, H-4’), 1.87 (m, 2H, H-5’), 1.87 (masked, 1H, H-3ax), 1.95 (m, 1H, 
H-5), 2.05 (m, 1H, H-4eq), 2.35 (masked, 1H, CH2py), 2.40 (t, J = 6.0 Hz, 2H, H-
2’), 2.60 (1H, m, H-8eq), 2.70 (m, 1H, CH2py), 2.96 (s, 3H, NCH3), 3.21 (br t, J = 
12.0 Hz, 1H, H-8a), 3.42 (td, J = 12.0, 3.0 Hz, 1H, H-2ax), 3.61 (br d, J = 12.0 





18.2 (CH3), 19.2 (C-4’), 22.9 (C-3), 23.3 (C-5’), 27.1 (C-4), 27.2 (C-7), 29.9 (C-
3’), 30.2 (C-8), 34.6 (C-5), 35.5 (CH2py), 37.5 (C-6), 44.7 (C-4a), 48.0 (NCH3), 
58.6 (C-6’), 71.1 (C-2), 75.9 (C-8a), 147.2 (C-2’); 15N (50 MHz, deduced from 
1H-15N HMBC correlations) δ 113.8 (N-oxide), 271.0 (nitrone). HRMS (ESI-TOF) 




Tables for 1H and 13C NMR data of synthetic serralongamine A (2, free base 
and diprotonated sample) and huperzine N (1) as well as NMR data of isolated 
alkaloids. Copies of 1H and 13C NMR spectra of new compounds. COSY, 
TOCSY, ROESY, HSQC, HMBC, and 1H-15N HMBC spectra of Huperzine N (1) 
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